IMCR Stock Analysis: Buy, Sell, or Hold?
IMCR - Immunocore Holdings plc American Depositary Shares
$29.91
0.71 (2.43%)
▲
5d:
+6.18%
30d:
+3.75%
90d:
-0.12%
BUY
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When IMCR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: IMCR shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: IMCR shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: IMCR is currently trading at $29.91, which is considered extended relative to its 30-day fair value range of $28.30 to $29.40.
Technical Outlook: Technically, IMCR is in a strong downtrend. The price is approaching resistance at $30.05. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: IMCR has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $63.49 (+117.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, IMCR is in a strong downtrend. The price is approaching resistance at $30.05. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: IMCR has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $63.49 (+117.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$28.30 -
$29.40
Company Quality Score
64/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 117.4% below Wall St target ($63.49)
Trading Range Analysis
30-Day Trading Range
$28.30 -
$29.40
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$27.59
Resistance Level
$30.05
Current Trend
Strong Downtrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-43.46
Wall Street Target
$63.49
(+117.4%)
Revenue Growth (YoY)
13.6%
Earnings Growth (YoY)
150.0%
Profit Margin
-6.7%
Share & Embed Analysis
Last updated: June 24, 2026 11:44 AM ET
Data refreshes hourly during market hours. Next update: 12:44 PM
Data refreshes hourly during market hours. Next update: 12:44 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IMCR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Bahija Jallal
SELL
11474 shares
2026-02-18
David M Berman
SELL
5965 shares
2026-02-18
John Goll
SELL
698 shares
2026-02-18
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 54 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$31 | 62 BUY |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$122 | 55 HOLD |
|
DYN
Dyne Therapeutics Inc |
STRONG BUY
14 analysts |
$38 | 62 BUY |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$128 | 57 HOLD |
